Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Apr 26, 2021 9:12am
131 Views
Post# 33065596

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TH's website issues

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:TH's website issuesWasn't planning on any written stuff agreed upon with them. This shouldn't be confrontational and I certainly don't want that. Like I said, I will bet my bottom  dollar on it they are equally frustrated and agree we are working toward the exact same goal. We just have a view on who we should draft for the team to win the cup.

SPCEO1 wrote: I agree. Let's just let Wino handle this however he thinks best.
palinc2000 wrote:

I dont think having them agree to a wrtten summary of the meeting is s good idea ....
Creating a sense of legal liability is not the way to have an open , frank discussion ... on the contrary !

 

scarlet1967 wrote:

 

I am not overly optimistic but since you have made the effort I would like to point out few things although you probably know:
1-You are not as good as they you are BETTER.
2-It seems you have already prepared your pitch with few requests, don’t let them bargain it is NOT a negotiation.
3-You can elaborate on your requests but most of the conversation should be about their responses.
4-Stay on topics don’t let them distract you from the purpose of the meeting.
5-If they can’t present solid plans to address the issues schedule another meeting as soon as possible so the company can respond with concrete solutions.
6-Leave the door open for future conversations so the company can interact with the shareholders on an ongoing basis.
5-Ideally everything should be in writing but since this is an informal meeting it would be a good idea if you could draft a summary of the meeting and email it back to the company for their review/approval before reporting back to the investors so there is an element of liability to the whole exercise.
 

Wino115 wrote: The only person I contacted was Paul.  Although, I have noticed a ton of people with familiar names pinged my LinkedIn.

Bucknelly21 wrote:
 
great who contacted you wino?
 

 

 

 




<< Previous
Bullboard Posts
Next >>